Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic.

Trends in pharmacological sciences - 1 Sept 2025

Papavassiliou Kostas A, Vassiliou Alice G, Papavassiliou Athanasios G

Abstract excerpt

KRASG12V-driven cancers remain therapeutically elusive. Recently, Stanland and colleagues developed EFTX-G12V, a GE11-conjugated small interfering RNA (siRNA) that selectively silences KRASG12V and achieves tumor regression by inhibiting oncogenic signaling and angiogenesis and enhancing anti-tumor immunity. EFTX-G12V represents an innovative RNAi-based precision oncology strategy for previously undruggable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Neoplasms
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to RNA Interference

Share to RNA, Small Interfering

Source

Identifiers

PMID: 40713293
DOI: 10.1016/j.tips.2025.07.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic.PMID 40713293Read ↗

A first-in-class EGFR-directed KRAS G12V selective inhibitor.Semantic proximity Read ↗

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Semantic proximity Read ↗

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Targeting the Yin and Yang of KRASG12C.Semantic proximity Read ↗

Targeting the undruggable oncogenic KRAS: the dawn of hope.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.